ERBB2 and breast cancer: Compare PFS (noninferiority design) between HER2‐negative, hormone receptor‐positive metastatic BC patients randomized to a clinician‐driven or a CTC‐driven choice of first‐line treatment (chemotherapy if ≥ 5/7.5mL using the CellSearch® system, endocrine therapy if < 5 CTCs/7.5mL)